By notice dated March 5, 2004, and published in the Federal Register on March 15, 2004, (69 FR 12180), Roche Diagnostics Corporation, Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances:
| Drug | Schedule |
|---|---|
| Lysergic Acid Diethylamide (7315) | I |
| Tetrahydrocannabinols (7370) | I |
| Alphamethadol (9605) | I |
| Phencyclidine (7471) | II |
| Benzoylecgonine (9180) | II |
| Methadone (9250) | II |
| Morphine (9300) | II |
The company plans to produce small quantities of controlled substances for use in diagnostic products.
No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Roche Diagnostics Corporation, to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Roche Diagnostics Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.
Dated: July 8, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-16384 Filed 7-17-04; 8:45 am]
BILLING CODE 4410-09-M